Attendee search 

Almac provides a comprehensive range of integrated services from research through to commercialisation.  Almac is a financially stable, privately owned organisation with over 3,300 employees located within the US and UK. Over 95% of work is repeat business, testament itself to the quality, innovation, efficiency and the high level of customer satisfaction provided.   

Services Offered
Almac’s integrated solutions extend from research to commercialisation and include:

Biomarker Discovery & Development:
·         Companion Diagnostic Development
·         Genomic Services
·         Bioinformatics Consultancy
·         Proprietary Discovery Arrays 

API Services & Chemical Development:
·         API Development & Manufacture
·         Peptide & Protein Technology
·         Accelerated First in Man Solution
·         Solid State Services
·         Isotope Chemistry
·         Biocatalysis
     
Pharmaceutical Development: 
·         Preformulation & Early Stage Development
·         Scale Up and Late Stage Development
·         Clinical Trial Manufacture
·         Contained Development & Manufacture

Analytical Services:
·         Physical & Chemical Characterisation
·         Method Development & Validation
·         API & Drug Product Testing
·         Stability Testing

Clinical Trial Supply:
·         Comparator Blinding
·         Packaging & Labelling
·         QP Release
·         Global Distribution & Supply Chain Management

Clinical Technologies:
·         IVR / Web
·         ePRO
·         Statistical Services

Commercial Services
·         Manufacturing & Packaging
·         Product Launch & Distribution

Come and see us at booth #64

MiNA Therapeutics is a virtual biotechnology company pioneering the activation of gene expression with short activating RNA (saRNA).

Harnessing a proprietary algorithm, MiNA is developing a revolutionary class of therapeutics that activate key genes in major disease pathways. MiNA's ability to selectively activate master regulatory genes represents a new frontier in precision medicine.

Sphere Fluidics Limited is an innovative Life Sciences company which delivers miniaturised products, systems and collaboration services in field of single cell analysis.

Sphere’s core technology is in the field of high throughput Picodroplet generation and analysis and has significant patent portfolio that protects its core expertise. It enables ultra-high throughput analysis of single cells and generation of their genetic, transcriptomic and proteomic profiles in miniaturised (pl to nl) volumes.  

Uniquely, as well as allowing single cell studies, the systems enable the study of different, large biomolecules that interact with or are secreted by those single cells. The latter application is very powerful as many human biotherapeutics, industrial enzymes (isolated mainly from micro-organisms) and around 15% of the Human Proteome are secreted, so cannot readily be analysed using conventional technology

Sphere Fluidics' technology enables diverse applications such as study of the mechanism of cancer cell resistance to chemotherapy, generation of new enzymes and identification of novel microbial strains.

Sphere Fluidics has established multiple commercial partnerships, received Venture Capital investment and with its founders the Company have received almost £10 million in science and business funding to date.

CrystecPharma applies the latest supercritical fluid (SCF) technologies to improve the design and performance of medicines. We provide crystal and particle engineering solutions to the pharmaceutical industry, contributing to human health by enabling new and more effective therapies.

Crystec SCF technologies can be applied to both small drug molecules and biomolecules.
Our services include crystal form screening and particle design, addressing issues of poor solubility and stability, improved delivery, and product enhancement in support of lifecycle management.

We are also engaged in in-house programmes to develop improved small and large molecule therapeutic products.

Our objectives this year at BioEurope are to identify new clients wishing to enhance the performance of their small and large moilecule therapeutics as well as identifying co-development partners, for supergeneric and new drugs.

About Competitive Drug Development International Ltd.

CDDI is an international biotechnology and pharmaceutical consulting company, led by senior people who together have developed more than 20 products globally from discovery to market. CDDI can give support with a broad range of drug development activities across the three key disciplines of Clinical, Non-clinical and CMC.

Services include Virtual Asset Development (VAD), where CDDI provides a fully integrated development team directed by strong project leadership, Evidence Based Protocol Feasibility (ebf) for data-driven and rapid patient recruitment, and CMC services from API and formulation development of NCEs and NBEs, through to CMO management of GMP manufacturing.

Our working method is hands-on, not just consulting, which means, we don’t just advise you, but actively implement the strategies and plans that we formulate with you. For more information please visit www.cddi.co.

QCTR is the ONLY CRO to focus exclusively on clinical trials in CNS.
With its subjective assessments and often subjective diagnosis, along with lack of biomarkers and high placebo response, CNS offers unique challenges. 
QCTR have over 15 years of experience in CNS covering diseases as diverse as Alzheimer's, TBI, stroke and schizophrenia, and orphan diseases such as Huntington's and FTD.

With a worldwide network of experienced clinicans working in neurology and psychiatry, and experienced staff knowledgable in the therapeutic field, we can plan and execute cost effective clinical trials to meet your company's specific requirements.

Avillion was registered in London UK in December 2012 and we are fully financed by the venture capital groups Abingworth and Clarus ventues. We are a company focused on co-development and financing of late-stage programs, where we provide partners with 100% financing for regulatory approval studies with the intent of accelerating the approval of drugs in the US and the EU.

We offer partners an unique and attractive option for the advancement of their pipeline- where we incur 100% of the clinical and regulatory risk of a program, thereby enabling partners to limit their P&L burden and have an advantageous financial position (EPS preservation).

Epistem is a biotechnology company with a specialist understanding of epithelial tissue and stem cell analyses, operating three distinct business divisions.

The Contract Research Division delivers innovative preclinical research services in the areas of oncology (inc. leukaemia), mucositis, inflammatory bowel disease, rheumatoid arthritis, wound healing and skincare. Working with over 200 pharmaceutical, biotechnology, and personal care companies worldwide, it offers proprietary assays for target validation, screening, efficacy, and translational biology using some of the latest technology, including small animal imaging, and with a GCLP accredited histology suite.

The Personalised Medicine Division is committed to facilitating a more tailored approach to patient treatment and care. It applies innovative gene expression technology to discovering novel drug-induced biomarkers to GCLP standard. It has also developed Genedrive™, a ‘point of care’ molecular diagnostic device providing a ‘near patient’ diagnosis in less than 30 minutes using hand held apparatus.

Our Novel Therapies Division is identifying the key regulators (proteins and peptides) of epithelial stem cells with the aim of developing therapeutics to control cell production.

Almac provides a comprehensive range of integrated services from research through to commercialisation.  Almac is a financially stable, privately owned organisation with over 3,300 employees located within the US and UK. Over 95% of work is repeat business, testament itself to the quality, innovation, efficiency and the high level of customer satisfaction provided.   

Services Offered
Almac’s integrated solutions extend from research to commercialisation and include:

Biomarker Discovery & Development:
·         Companion Diagnostic Development
·         Genomic Services
·         Bioinformatics Consultancy
·         Proprietary Discovery Arrays 

API Services & Chemical Development:
·         API Development & Manufacture
·         Peptide & Protein Technology
·         Accelerated First in Man Solution
·         Solid State Services
·         Isotope Chemistry
·         Biocatalysis
     
Pharmaceutical Development: 
·         Preformulation & Early Stage Development
·         Scale Up and Late Stage Development
·         Clinical Trial Manufacture
·         Contained Development & Manufacture

Analytical Services:
·         Physical & Chemical Characterisation
·         Method Development & Validation
·         API & Drug Product Testing
·         Stability Testing

Clinical Trial Supply:
·         Comparator Blinding
·         Packaging & Labelling
·         QP Release
·         Global Distribution & Supply Chain Management

Clinical Technologies:
·         IVR / Web
·         ePRO
·         Statistical Services

Commercial Services
·         Manufacturing & Packaging
·         Product Launch & Distribution

Come and see us at booth #64

Oxford BioMedica (LSE:OXB) is a leading gene therapy and immunotherapy company with a platform of exclusive and pioneering technologies to design, develop and manufacture unique gene-based medicines. The Company’s technology platforms include a highly efficient LentiVector® gene delivery system; a single administration to provide long-lasting therapy with specific advantages for targeting CNS and ocular diseases, and a unique tumour antigen (5T4) which is an ideal target for anti-cancer therapy.

The Company’s pipeline addresses diseases for which there is currently no treatment or that are inadequately treated today, including ocular diseases, neurodegenerative disorders and cancer, and its product candidates have the potential to transform treatment landscapes.  Oxford BioMedica’s capabilities cover the entire product lifecycle, from research to development to GMP manufacturing, with collaborative partners such as Sanofi, Pfizer, Novartis and some of the most prestigious clinical centres worldwide.  The Company recently secured significant funding via UK Government competitive awards such as the TSB regenerative medicine/cell therapy grant and AMSCI to build a centre of excellence for specialist manufacture of gene-based therapies.

Through in-house development programmes and industry collaborations, Oxford BioMedica’s goal is to improve the lives of patients with debilitating and life-threatening diseases.  Further information is available at www.oxfordbiomedica.co.uk and www.oxbsolutions.co.uk.